Jeremy J. Chen
Taitung, TNQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Proscillaridin A inhibits lung cancer cell growth and motility through downregulation of the EGFR-Src-associated pathway.
Journal: American journal of cancer research
Published: July 31, 2023
Peruvoside is a novel Src inhibitor that suppresses NSCLC cell growth and motility by downregulating multiple Src-EGFR-related pathways.
Journal: American journal of cancer research
Published: December 30, 2021
Paired-like homeodomain 2B contributes to tumour progression and anti-autophagy in human lung cancer.
Journal: American journal of cancer research
Published: July 05, 2021
Pharmacophore-based virtual screening for the identification of the novel Src inhibitor SJG-136 against lung cancer cell growth and motility.
Journal: American journal of cancer research
Published: November 12, 2019
Increased risk of community-acquired pneumonia in COPD patients with comorbid cardiovascular disease.
Journal: International journal of chronic obstructive pulmonary disease
Published: December 17, 2016
Oncogenic miR-137 contributes to cisplatin resistance via repressing CASP3 in lung adenocarcinoma.
Journal: American journal of cancer research
Published: February 05, 2016
Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma.
Journal: OncoTargets and therapy
Published: June 13, 2014
Tumour suppressor HLJ1: A potential diagnostic, preventive and therapeutic target in non-small cell lung cancer.
Journal: World journal of clinical oncology
Published: December 27, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026